These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://siobhanvges782104.life3dblog.com/37704238/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide